Skip to main content
Premium Trial:

Request an Annual Quote

Pyrosequencing, Mosaic Enter Cross-Licensing Deal

NEW YORK, March 20 – Pyrosequencing of Uppsala Sweden and Mosaic Technologies said Tuesday they had signed a cross-licensing agreement for access to their complementary DNA sequencing technologies.

Under the terms of the deal, Pyrosequencing will have co-exclusive rights to Mosaic's fluorescent detection technology. In exchange, Mosaic will have access to Pyrosequencing's “sequencing by synthesis” technology to use in combination with its "sequencing on amplified polony array" technology.

"Access to the Mosaic technology provides us with a simple and straight forward method for implementing our Pyrosequencing technology in new miniaturized platforms such as microfluidics and array formats," said Bjorn Ekstrom, chief technology officer at Pyrosequencing. "It also gives Pyrosequencing the ability to develop products with integrated sample preparation, potentially shorter cycle times, and longer sequencing reads, and the opportunity to enter new market segments like expression profiling."

Pyrosequencing, which has developed a sequencing technique comprised of an enzymatic cascade and a chemiluminescent detection system that results in a light flash every time a unique position in the DNA strand is detected, said Mosaic’s technology would enable the company to produce diagnostics. Pyrosequencing’s technology is currently designed to help researchers sequence DNA as well as identify SNPs.

Mosaic noted that rights to Pyrosequencing’s technology would give the company a broader IP base, which would help it to commercialize new products using array-based sequencing technology. Mosaic exploits solid phase chemistry to purify, amplify, and detect DNA.

Mosaic is currently developing five products to improve DNA microarrays and high-throughput sequencing. The company hopes to launch these products during the next three years through corporate alliances.

The companies did not disclose the financial terms of the deal.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.